Huyabio International has concluded the Phase I drug-drug interaction clinical trial of its drug, HBI-3000, for cardioversion of atrial fibrillation (AF).
A multi-ion channel blocker, HBI-3000 possesses in vitro inhibitory effects on INa-Peak, INa-Late, ICa, L and IKr.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Its preclinical and clinical pharmacology supports the potential for restoring sinus rhythm in AF.
Furthermore, in preclinical testing, HBI-3000 showed a reduced risk for proarrhythmia.
The Phase I trial analysed the safety and pharmacokinetics (PK) of HBI-3000 when administered along with paroxetine, a CYP2D6 inhibitor.
Findings showed that no substantial PK interaction was observed between paroxetine and HBI-3000.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBased on the initial safety and pharmacokinetic data from the Phase I trial, the US Food and Drug Administration granted approval for dose escalation in the Phase II HBI-3000-402 clinical trial.
The two-stage, serial cohort dose-escalation and expansion study will assess a single 30-minute intravenous (IV) infusion of HBI-3000 for the conversion of patients with recent-onset AF.
This trial will analyse the pharmacological cardioversion of acute AF.
Carried out usually using high-energy electrical shock, cardioversion intends to reinstate a normal heart rate and rhythm in AF patients.
Huyabio International president, CEO and executive chair Dr Mireille Gillings said: “I am pleased to announce this positive step in the development of HBI-3000 for potential use in patients suffering from AF, a serious condition that affects more than 30 million people worldwide.
“The successful completion of this Phase I will enable progression of the ongoing Phase II trial investigating efficacy of HBI-3000 for the conversion of acute AF.”
